Endobronchial Ultrasound Biopsy Market Growing at 5.84% CAGR, Expected to Reach USD 1.25 Billion by 2033 - Strategic Revenue Insights

London, UK - November 2025 | Strategic Revenue Insights Inc. - The global Endobronchial Ultrasound Biopsy (EBUS Biopsy) market continues to gain considerable traction, with our latest research showing the market growing from USD 751.60 million in 2024 to a projected USD 1.25 billion by 2033.

This growth translates into a compound annual growth rate (CAGR) of 5.84 %, as rising disease burden and improvements in diagnostic technology push broader adoption of EBUS procedures.

The progression from USD 751.60 million in 2024 to USD 1.25 billion by 2033 marks an increase of nearly USD 500 million over the forecast period a result of increasing reliance on minimally invasive diagnostic procedures for lung and thoracic conditions. The market showed earlier growth between 2018 and 2024, as clinicians moved away from more invasive surgical diagnostics toward image-guided biopsy techniques that offer lower risk and faster recovery times.

A comprehensive assessment of this rapidly evolving market can be accessed through Strategic Revenue Insights at the link below, focused on Endobronchial Ultrasound Biopsy:

https://www.strategicrevenueinsights.com/industry/endobronchial-ultrasound-biopsy-market

Rising prevalence of lung cancer, chronic respiratory diseases, and growing awareness about early detection of thoracic conditions form the core demand drivers. As healthcare providers and patients increasingly favor procedures that reduce invasiveness and improve diagnostic accuracy, demand for EBUS systems has grown. Concurrently, ongoing technological advances including improvements in ultrasound imaging resolution, biopsy needle design, and real-time navigation have enhanced the safety, reliability, and usability of EBUS biopsy procedures, further encouraging adoption.

Regional market dynamics show clear variation. Mature healthcare systems in North America continue to dominate the market share, driven by established hospital infrastructure, high incidence of respiratory disorders, and greater capacity for diagnostic investment. At the same time, the Asia-Pacific region and other emerging economies are showing the fastest growth rates, supported by rising healthcare expenditure, expanding diagnostic infrastructure, and growing demand for minimally invasive procedures in both urban and rural settings.

Browse the associated report:

https://www.strategicrevenueinsights.com/ja/industry/endobronchial-ultrasound-biopsy-market

https://www.strategicrevenueinsights.com/kr/industry/endobronchial-ultrasound-biopsy-market

https://www.strategicrevenueinsights.com/da/industry/endobronchial-ultrasound-biopsy-market

The competitive landscape in the EBUS biopsy market features major global medical-device companies and specialized diagnostic-equipment manufacturers. While the report by Strategic Revenue Insights highlights firms like Siemens Healthiness as well positioned due to their focus on advanced diagnostic solutions, the broader space also includes other well-known players offering scopes, needles, imaging processing systems and associated consumables.

Segmentation analysis reveals a clear breakdown by component, application, and end user. By component, the market includes EBUS scopes, biopsy needles, imaging/ultrasound processors and related accessories with scopes typically holding a significant share because of their role in real-time navigation and tissue sampling.

By procedure type, EBUS-guided transbronchial needle aspiration remains the most common, serving a majority of diagnostic biopsy needs for lung cancer and mediastinal lymph node evaluation. End users predominantly include hospitals, diagnostic centers, and specialty clinics though ambulatory surgical centers and outpatient diagnostic facilities are gaining traction as EBUS procedures become more accessible and demand increases.

Looking ahead toward 2033 and beyond, the EBUS biopsy market appears set for steady growth as global healthcare systems continue to emphasize early diagnosis, minimally invasive procedures, and efficient patient throughput. Upgrades in ultrasound imaging technology, broader availability of equipment in emerging markets, and increased training of skilled professionals are likely to drive further adoption.

Particularly in regions with rising lung disease burden, expansion of diagnostic centers, and growing healthcare budgets including parts of Asia-Pacific, Latin America, and the Middle East the opportunity for market expansion remains substantial. Continuous innovation in device design (lighter scopes, more precise needles, integrated imaging & analytics) and favorable healthcare policies supporting early detection will likely push the market past the USD 1.25 billion mark, potentially even higher as procedure costs decrease and accessibility improves.

Related Reports:

https://www.strategicrevenueinsights.com/industry/osteoarthritis-topical-diclofenac-market

Media Contact

Company Name: Strategic Revenue Insights Inc.

Contact Person: Ashwani

Email: sales@strategicrevenueinsights.com

Phone: +44 7877 403352

Address: Suite 10, Capital House, 61 Amhurst Road, E8 1LL

City: London

Country: United Kingdom

Website: www.strategicrevenueinsights.com

Website: www.strategicpackaginginsights.com

About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd, empowers organizations worldwide with data driven market intelligence. Headquartered in London, United Kingdom, the firm delivers syndicated research reports, tailored consulting solutions, and actionable insights that equip clients to make confident, future focused strategic decisions. Its team of seasoned analysts continuously tracks markets, identifies emerging trends, and uncovers growth opportunities to support long-term client success. As part of SRI Consulting Group Ltd, Strategic Revenue Insights Inc. is committed to accuracy, clarity, and practical relevance, helping businesses optimize strategies and accelerate revenue growth.

This release was published on openPR.